<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548400" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548400/" /><meta name="ncbi_pagename" content="Corticosteroids - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Corticosteroids - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Corticosteroids" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/10/30" /><meta name="citation_pmid" content="31643719" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548400/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Corticosteroids" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/10/30" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548400/" /><meta name="description" content="The corticosteroids are a group of chemically related natural hormones and synthetic agents that resemble the human adrenal hormone cortisol and have potent antiinflammatory and immunosuppressive properties and are widely used in medicine. Corticosteroid therapy is associated with several forms of liver injury, some due to exacerbation of an underlying liver disease and some that appear to be caused directly by corticosteroid therapy. This discussion will cover eight agents: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone." /><meta name="og:title" content="Corticosteroids" /><meta name="og:type" content="book" /><meta name="og:description" content="The corticosteroids are a group of chemically related natural hormones and synthetic agents that resemble the human adrenal hormone cortisol and have potent antiinflammatory and immunosuppressive properties and are widely used in medicine. Corticosteroid therapy is associated with several forms of liver injury, some due to exacerbation of an underlying liver disease and some that appear to be caused directly by corticosteroid therapy. This discussion will cover eight agents: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548400/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Corticosteroids/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548400/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CFAB10466D5810000000003A00108.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548400_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548400_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Copper/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Crizotinib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548400_"><span class="title" itemprop="name">Corticosteroids</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 30, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Corticosteroids.OVERVIEW"><h2 id="_Corticosteroids_OVERVIEW_">OVERVIEW</h2><div id="Corticosteroids.Introduction"><h3>Introduction</h3><p>The corticosteroids are a group of chemically related natural hormones and synthetic agents that resemble the human adrenal hormone cortisol and have potent antiinflammatory and immunosuppressive properties and are widely used in medicine. Corticosteroid therapy is associated with several forms of liver injury, some due to exacerbation of an underlying liver disease and some that appear to be caused directly by corticosteroid therapy. This discussion will cover eight agents: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone.</p></div><div id="Corticosteroids.Background"><h3>Background</h3><p>The corticosteroids are hormones that have glucocorticoid (cortisol-like) and/or mineralocorticoid (aldosterone-like) activities and which are synthesized predominantly by the adrenal cortex. In clinical practice, the term &#x0201c;corticosteroids&#x0201d; usually refers to the glucocorticoids and are represented by a large group of natural or synthetic steroid compounds that have varying potency, durations of action and relative glucocorticoid (measured by antiinflammatory activity) vs mineralocorticoid (measured by sodium retention) activities. Cortisol and the corticosteroids act by engagement of the intracellular glucocorticoid receptor, which then is translocated to the cell nucleus where the receptor-ligand complex binds to specific glucocorticoid-response elements on DNA, thus activating genes that mediate glucocorticoid responses. The number of genes modulated by corticosteroids are many and the effects are multiple and interactive with other intracellular pathways. Thus, the effects of corticosteroids on inflammation and the immune system cannot be attributed to a single gene or pathway. The potent antiinflammatory and immunosuppressive qualities of the corticosteroids have made them important agents in the therapy of many diseases. Corticosteroids are available in multiple forms, including oral tablets and capsules; powders and solutions for parenteral administration; topical creams and lotions for skin disease; eye, ear and nose liquid drops for local application; aerosol solutions for inhalation and liquids or foams for rectal application. Representative corticosteroids (and the year of their approval for use in the United States) include cortisone (1950), prednisone (1955), prednisolone (1955), methylprednisolone (1957), dexamethasone (1958), betamethasone (1961), and hydrocortisone (1983). All are available in generic forms. In this website, only the oral and intravenous formulations of corticosteroids are described and they are discussed together with common list of references and representative case reports.</p><p>The corticosteroids are used widely in medicine largely for their potent antiinflammatory and immunosuppressive activities. The clinical conditions for which corticosteroids are used include, but are not limited to: asthma, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, inflammatory bowel disease, nephritic syndrome, cancer, leukemia, organ transplantation, autoimmune hepatitis, hypersensitivity reactions, cardiogenic and septic shock, and, of course, glucocorticoid deficiency diseases such as in Addison&#x02019;s disease and panhypopituitarism.</p><p>Corticosteroids are used in several liver diseases, most commonly in autoimmune hepatitis for which they have been shown to improve outcome and survival. Corticosteroids are also used after liver transplantation to prevent rejection. An important element in managing these liver diseases and conditions is to maintain the dose of corticosteroids at the lowest effective level. The adverse effects of long term corticosteroid therapy (which are rarely hepatic) are still major causes of morbidity and even mortality in these conditions.</p><p>Prednisone, prednisolone, methylprednisone and triamcinolone are the most commonly used oral agents as they are inexpensive, rapid in onset, intermediate in duration of action and have potent glucocorticoid with minimal mineralocorticoid activities, at least as compared to cortisone and hydrocortisone. Betamethasone and dexamethasone have greater glucocorticoid potency and less aldosterone-like activity than prednisone, but have a longer duration of action, and they are mostly used in topical or liquid forms for local application and in injectable forms for severe hypersensitivity reactions and inflammation. Methylprednisone and hydrocortisone are most commonly used for intravenous administration, typically given in emergency or critical situations in which rapid and profound immunosuppression or antiinflammatory activity is needed.</p><p>The table below provides the major forms of corticosteroids and their relative glucocorticoid and mineralocorticoid activity and equivalent daily doses.</p><div id="Corticosteroids.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Corticosteroids.Tc_1_1_1_1" colspan="4" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:top;">RELATIVE POTENCIES OF CORTICOSTEROIDS</th></tr><tr><th headers="hd_h_Corticosteroids.Tc_1_1_1_1" id="hd_h_Corticosteroids.Tc_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">AGENT</th><th headers="hd_h_Corticosteroids.Tc_1_1_1_1" id="hd_h_Corticosteroids.Tc_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">GLUCOCORTICOID ACTIVITY</th><th headers="hd_h_Corticosteroids.Tc_1_1_1_1" id="hd_h_Corticosteroids.Tc_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MINERALOCORTICOID ACTIVITY</th><th headers="hd_h_Corticosteroids.Tc_1_1_1_1" id="hd_h_Corticosteroids.Tc_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">EQUIVALENT ORAL OR INTRAVENOUS DOSE</th></tr></thead><tbody><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cortisol</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cortisone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisolone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methylprednisolone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.5</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Triamcinolone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Betamethasone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.75</td></tr><tr><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dexamethasone</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Corticosteroids.Tc_1_1_1_1 hd_h_Corticosteroids.Tc_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.75</td></tr></tbody></table></div></div><p><b>Cortisone</b> (kor' ti sone) is a short acting glucocorticoid that is used for therapy of adrenal insufficiency and for treatment of allergic and inflammatory conditions. Cortisone is available in generic forms in tablets of 25 mg, which is considered a daily physiologic dose in adults. Cortisone has both glucocorticoid and mineralocorticoid properties.</p><p><b>Hydrocortisone</b> (hye" droe kor' ti sone) is a rapid and short acting glucocorticoid that is used for therapy of adrenal insufficiency and in treatment of allergic and inflammatory conditions. Hydrocortisone has the same chemical structure as cortisol and thus most closely resembles the human adrenal hormone. Hydrocortisone is available in generic forms in tablets of 5, 10 and 20 mg, with 20 mg being considered a daily physiologic dose in adults. Hydrocortisone is also available in multiple forms in solution for oral, rectal, topical or parenteral administration. A major use of intravenous hydrocortisone is in the acute therapy of severe hypersensitivity reactions and shock. Hydrocortisone has both glucocorticoid and mineralocorticoid properties.</p><p><b>Prednisone</b> (pred' ni sone) is a synthetic, intermediate acting glucocorticoid that is widely used in the therapy of severe inflammation, autoimmune conditions, hypersensitivity reactions and organ rejection. Prednisone is converted to prednisolone, its active form, in the liver. Prednisone is available in multiple generic forms in tablets of 1, 2.5, 5, 10, 20 and 50 mg and as oral solutions. Four times more potent that cortisol, prednisone is used in varying doses, with 5 mg daily being considered physiologic doses in adults.</p><p><b>Prednisolone</b> (pred nis' oh lone) is a synthetic, intermediate acting glucocorticoid that is widely used in the therapy of severe inflammation, autoimmune conditions, hypersensitivity reactions and organ rejection. Prednisolone is available in multiple generic forms in tablets of 5, 10, 15 and 30 mg and in several forms for systemic administration. Four times more potent that cortisol, prednisolone is used in varying doses, with 5 mg daily being considered physiologic doses in adults.</p><p><b>Methylprednisolone</b> (meth" il pred nis' oh lone) is a synthetic, intermediate acting glucocorticoid that is widely used in the therapy of severe inflammation, autoimmune conditions, hypersensitivity reactions and organ rejection. Methylprednisolone is available in multiple forms in tablets of 2, 4, 8, 16 and 32 mg generically and under the brand name of Medrol and in Medrol Dosepaks (21 tablets of 4 mg each). Injectable forms of methylprednisolone are also available generically and under brand names of Solu-Medrol and Depo-Medrol. Five times more potent that cortisol, methylprednisolone is used in varying doses, with 4 mg daily being considered physiologic doses in adults. Methylprednisolone has minimal mineralocorticoid activity.</p><p><b>Triamcinolone</b> (trye" am sin' oh lone) is a synthetic, long acting glucocorticoid that is used in topical solutions and aerosols for therapy of allergic and hypersensitivity reactions and control of inflammation as well as in parenteral formulations for therapy of hypersensitivity reactions, shock and severe inflammation. Oral forms of triamcinolone include tablets of 4 and 8 mg and oral syrups. Parenteral forms for injection are available under various generic and trade names including Aristocort and Kenacort. Triamcinolone is five times more potent than cortisol in its glucocorticoid activity, but has minimal mineralocorticoid activity.</p><p><b>Dexamethasone</b> (dex" a meth' a sone) is a synthetic, long acting glucocorticoid that is used parenterally as therapy of severe hypersensitivity reactions, shock and control of severe inflammation as well as in topical, otic, ophthalmologic solutions, aerosols and lotions or creams for local therapy of allergic reactions and inflammation. Dexamethasone is available in multiple forms for injection under various generic and trade names including Decadron. Dexamethasone is 25 times more potent than cortisol in its glucocorticoid activity, but has minimal mineralocorticoid activity.</p><p><b>Betamethasone</b> (bay" ta meth' a sone) is a synthetic, long acting glucocorticoid that is used in parenteral forms for therapy of allergic and hypersensitivity reactions and control of severe inflammation. Betamethasone is available in solution for injection under the trade name of Celestone and in multiple generic forms as syrups and effervescent tablets for oral use, edemas and foams for rectal use, aerosols for nasal and respiratory use, and creams and lotions for topical use. Betamethasone is 25 times more potent than cortisol in glucocorticoid activity, but has minimal mineralocorticoid activity.</p></div><div id="Corticosteroids.Hepatotoxicity_Mechanism"><h3>Hepatotoxicity, Mechanism of Injury</h3><p>Corticosteroids have multiple adverse side effects, due to their multiplicity of actions affecting virtually all organs. Long term use has very profound effects on growth and can lead to cataracts, glaucoma, opportunistic infections, thinning of the skin, weight gain and redistribution of fat, insulin resistance and diabetes, hypertension, headache, psychiatric problems, sodium retention and peripheral edema; all of the clinical features of Cushing syndrome.</p><p>Corticosteroids also have major effects on the liver, particularly when given long term and in higher than physiologic doses. Glucocorticoid use can result in hepatic enlargement and steatosis or glycogenosis. Corticosteroids can trigger or worsen nonalcoholic steatohepatitis. Long term use can also exacerbate chronic viral hepatitis. Importantly, treatment with corticosteroids followed by withdrawal or pulse therapy can cause reactivation of hepatitis B and worsening or de novo induction of autoimmune hepatitis, both of which can be fatal. Finally, high doses of intravenous corticosteroids, largely methylprednisolone, have been associated with acute liver injury which can result in acute liver failure and death. Thus, the hepatic complications of corticosteroids usually represent the worsening or triggering of an underlying liver disease and rarely are the result of drug hepatotoxicity.</p><p>Corticosteroid therapy can cause hepatic steatosis and hepatic enlargement, but this is often not clinically apparent, particularly in adults. This effect can occur quite rapidly and is rapidly reversed with discontinuation. High doses and long term use has been associated with the development or exacerbation of nonalcoholic steatohepatitis with elevations in serum aminotransferase levels and liver histology resembling alcoholic hepatitis with steatosis, chronic inflammation, centrolobular ballooning degeneration and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.mallory-bodies/">Mallory bodies</a> (Case 1). However, symptomatic or progressive liver injury from corticosteroid induced steatohepatitis is uncommon. Furthermore, corticosteroids may act to worsen an underlying nonalcoholic fatty liver disease rather than causing the condition de novo. The worsening may be due to direct effects of glucocorticoids on insulin resistance or fatty acid metabolism or may be the result of weight gain which is common with long term corticosteroid therapy. While simple steatosis induced by corticosteroids is rapidly reversible, steatohepatitis can be slow to resolve upon withdrawal of corticosteroids.</p><p>Corticosteroids in high doses can also cause hepatic glycogenosis, in which liver cells exhibit a homogenous appearance and stain strongly for glycogen (using PAS staining with and without diastase). Glycogenosis can also be associated with hepatomegaly (in children) and elevations in serum aminotransferase levels with minimal or no change in alkaline phosphatase or bilirubin levels. Glycogenosis is usually asymptomatic and does not appear to progress to chronic liver injury, cirrhosis or acute liver failure. While glycogenosis has been described largely in patients with poorly controlled type 1 diabetes, it also can occur acutely in patients started on high dose corticosteroids.</p><p>An important complication of corticosteroid therapy is the worsening of an underlying chronic viral hepatitis. In chronic hepatitis B, corticosteroids can induce increases in viral replication and serum hepatitis B virus (HBV) DNA levels while decreasing serum aminotransferase levels. Eventually, however, the increase in viral replication can worsen the underlying liver disease. Exacerbation of hepatitis becomes particularly evident when corticosteroids are withdrawn or lowered to physiological levels. As the immune system recovers, hepatitis worsens and serum aminotransferase levels can rise to greater than 10- to 20-fold elevated usually accompanied by a prompt decrease in HBV DNA levels. This flare of disease following withdrawal of corticosteroids can be severe and result in acute liver failure or significant worsening of chronic hepatitis and development of cirrhosis (Case 2). Indeed, even patients with the &#x0201c;inactive carrier states&#x0201d; (as shown by the presence of HBsAg in serum without HBeAg or detectable HBV DNA or any elevation in serum aminotransferase levels) can suffer severe reactivation of disease and acute liver failure as a result of a short course of high dose corticosteroids as occurs with cancer chemotherapy or with treatment of severe autoimmune conditions or even asthma, hay fever or allergic dermatitis. Reactivation of hepatitis B can be prevented by prophylactic use of antiviral therapy during the period of immunosuppression, but even this may not prevent some degree of liver injury.</p><p>Corticosteroids also appear to worsen the course of chronic hepatitis C, although in a less dramatic fashion than in chronic hepatitis B. Corticosteroid therapy leads to a rise in hepatitis C virus (HCV) RNA levels which may eventually cause worsening of the underlying liver disease. Chronic hepatitis C appears to be more severe and is particularly difficult to manage in patients receiving chemotherapy or immunosuppression, and corticosteroids are believed to be a major factor in this effect. Thus, corticosteroids should be avoided if possible in patients with underlying chronic viral hepatitis.</p><p>Corticosteroids are used in the therapy of autoimmune hepatitis and, therefore, are likely to be beneficial rather than harmful in patients with this disease. The difficulty arises when corticosteroids are stopped, which can cause a rebound exacerbation of the autoimmune hepatitis that is often severe and can be fatal. Importantly, there have been multiple reported instances of de novo appearance of severe autoimmune hepatitis in patients who received a short course or pulse of corticosteroids for another, unrelated condition (such as asthma or allergic reactions). In these situations, a mild and subclinical autoimmune hepatitis was likely present before corticosteroids were started, and the suppression of the disease followed by immune rebound caused the clinical presentation of the condition. These patients generally respond to restarting corticosteroids, but may require long term if not lifelong immunosuppressive treatment thereafter.</p><p>Finally, there have been several reports of an acute hepatitis-like liver injury arising after a short, high dose course of intravenous methylprednisolone that can be severe and even fatal, and in which viral hepatitis and autoimmune hepatitis cannot be clearly implicated (Case 3). The cause of this apparent hepatotoxicity is not known, but it may represent severe autoimmune hepatitis triggered by the sudden profound immunosuppression and subsequent immune reconstitution. Importantly, symptoms and jaundice develop 2 to 6 weeks after stopping methylprednisolone and the pattern of serum enzyme elevations is typically hepatocellular. These episodes are usually symptomatic and can be severe. Immunoallergic manifestations are uncommon and autoantibodies may not be present. Several instances have resulted in acute liver failure resulting in death or need for emergency liver transplantation. Restarting corticosteroids may be appropriate in this situation, but it has not been evaluated systematically and many instances have resolved spontaneously. Recurrence of injury, often in a more rapid and severe form, arises upon reexposure to high dose pulse methylprednisolone.</p><p>Likelihood score: A[HD] (well established cause of liver injury when given in high doses, either the result of reactivation of hepatitis B, or an acute hepatocellular injury after high dose intravenous treatment, particularly with methylprednisolone).</p><p>Drug Class: <a href="/books/NBK548400/">Corticosteroids</a></p><p>Selected Drugs in the Class: <a href="/books/NBK548400/">Betamethasone</a>, <a href="/books/NBK548400/">Cortisone</a>, <a href="/books/NBK548400/">Dexamethasone</a>, <a href="/books/NBK548400/">Hydrocortisone</a>, <a href="/books/NBK548400/">Methylprednisolone</a>, <a href="/books/NBK548400/">Prednisolone</a>, <a href="/books/NBK548400/">Prednisone</a>, <a href="/books/NBK548400/">Triamcinolone</a>. <a href="/books/n/livertox/Budesonide/">Budesonide</a> is also a corticosteroid but has not been linked to liver injury and is discussed separately in LiverTox.</p></div></div><div id="Corticosteroids.CASE_REPORTS"><h2 id="_Corticosteroids_CASE_REPORTS_">CASE REPORTS</h2><div id="Corticosteroids.Case_1_Nonalcoholic_stea"><h3>Case 1. Nonalcoholic steatohepatitis after long term corticosteroid therapy.(<a class="bk_pop" href="#Corticosteroids.REF.1">1</a>)</h3><p>A 34 year old woman with systemic lupus erythematosus was treated with betamethasone with good clinical response with improvements in rash, fatigue and laboratory tests. Over a 6 month period, the daily dosage was gradually decreased from 5 to 1.25 mg daily. Initially, her liver tests were normal, but with corticosteroid therapy, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> were mildly elevated (Table). However, after 16 months of therapy, serum aminotransferase levels were more than 5-fold elevated (ALT 256 U/L, AST 272 U/L) and she was readmitted for evaluation. Her weight had risen by 11 kilograms and she had firm hepatomegaly. Laboratory tests showed elevations in serum aminotransferase levels, but normal serum bilirubin, albumin, and prothrombin time. She had an abnormal glucose tolerance test (fasting 118 mg/dL, 2 hour postprandial glucose 248 mg/dL). Testing for HBsAg was negative. She was known to be positive for antinuclear antibody (1:128). She denied alcohol use, which was confirmed by family and friends. A liver biopsy showed marked steatosis with inflammation including neutrophils, occasional <a class="def" href="/books/n/livertox/glossary/def-item/glossary.mallory-bodies/">Mallory bodies</a> and mild central sinusoidal and portal fibrosis. Weight loss led to slight decreases in serum ALT levels.</p><div id="Corticosteroids.Key_Points"><h4>Key Points</h4><div id="Corticosteroids.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Td_lrgtbl__"><table><tbody><tr><th id="hd_b_Corticosteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Corticosteroids.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Betamethasone (1.25 mg daily)</td></tr><tr><th id="hd_b_Corticosteroids.Td_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Corticosteroids.Td_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular or mixed (R=~4.6)</td></tr><tr><th id="hd_b_Corticosteroids.Td_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Corticosteroids.Td_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mild (serum enzyme elevations only)</td></tr><tr><th id="hd_b_Corticosteroids.Td_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Corticosteroids.Td_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Several months</td></tr><tr><th id="hd_b_Corticosteroids.Td_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Corticosteroids.Td_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not mentioned</td></tr><tr><th id="hd_b_Corticosteroids.Td_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Corticosteroids.Td_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Corticosteroids.Laboratory_Values"><h4>Laboratory Values</h4><div id="Corticosteroids.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Corticosteroids.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Corticosteroids.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Body Weight<br />(kg)</th><th id="hd_h_Corticosteroids.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Corticosteroids.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Corticosteroids.Te_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Albumin<br />(g/dL)</th><th id="hd_h_Corticosteroids.Te_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Corticosteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Corticosteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">42.7</td><td headers="hd_h_Corticosteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_Corticosteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">95</td><td headers="hd_h_Corticosteroids.Te_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.4</td><td headers="hd_h_Corticosteroids.Te_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 months</td><td headers="hd_h_Corticosteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">52.2</td><td headers="hd_h_Corticosteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58</td><td headers="hd_h_Corticosteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62</td><td headers="hd_h_Corticosteroids.Te_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.9</td><td headers="hd_h_Corticosteroids.Te_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 months</td><td headers="hd_h_Corticosteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58.2</td><td headers="hd_h_Corticosteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">256</td><td headers="hd_h_Corticosteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">131</td><td headers="hd_h_Corticosteroids.Te_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.0</td><td headers="hd_h_Corticosteroids.Te_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protime 10.4 sec</td></tr><tr><td headers="hd_h_Corticosteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 months</td><td headers="hd_h_Corticosteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">55.5</td><td headers="hd_h_Corticosteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">134</td><td headers="hd_h_Corticosteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">76</td><td headers="hd_h_Corticosteroids.Te_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.2</td><td headers="hd_h_Corticosteroids.Te_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Te_1_1_1_1 hd_h_Corticosteroids.Te_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Corticosteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Corticosteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;85</b></td><td headers="hd_h_Corticosteroids.Te_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;3.5</b></td><td headers="hd_h_Corticosteroids.Te_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Corticosteroids.Comment"><h4>Comment</h4><p>This is an early, but well documented report of nonalcoholic steatohepatitis arising during corticosteroid therapy. The patient was evidently asymptomatic of liver disease, but the height of the serum aminotransferase elevations led to a hospital admission and liver biopsy. An issue is whether the liver disease was due to corticosteroid therapy directly or was the result of weight gain and insulin resistance caused by the therapy. Betamethasone is a synthetic, high potency glucocorticoid; 1.25 mg of betamethasone is roughly equivalent to 15 mg of prednisone.</p></div></div><div id="Corticosteroids.Case_2_Reactivation_of_c"><h3>Case 2. Reactivation of chronic hepatitis B by corticosteroids.(<a class="bk_pop" href="#Corticosteroids.REF.2">2</a>)</h3><p>A 69 year old man with ulcerative colitis and the HBsAg carrier state developed jaundice and hepatitis after 9 months of continuous prednisolone therapy and shortly after intravenous pulse treatment with methylprednisolone. He was known to be a carrier of HBsAg with normal serum aminotransferase levels and no detectable HBeAg or HBV DNA in serum for several years. Because of relapsing ulcerative colitis, he was started on prednisolone therapy in tapering doses (60 mg daily down to 5 mg daily). Approximately 8 months into therapy, he received a 7 day course of intravenous methylprednisolone. One week later, while still on low doses of oral prednisolone, he developed fatigue and nausea. Liver tests, which had been normal, were markedly elevated with <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 517 U/L, Alk P 356 U/L and bilirubin 3.98 mg/dL (Table). He was admitted. On examination, he was jaundiced and had mild mental dullness and asterixis. At this point, he tested positive for both HBsAg and HBeAg, and HBV DNA levels (which had been undetectable in the past) were markedly elevated (&#x0003e;100 million copies/mL). In addition he had IgM anti-HBc. Despite initiation of lamivudine therapy for hepatitis B and intensive medical management, he developed progressive liver failure, coagulopathy, hepatic coma and died 25 days after admission. Autopsy was refused.</p><div id="Corticosteroids.Key_Points_1"><h4>Key Points</h4><div id="Corticosteroids.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Tf_lrgtbl__"><table><tbody><tr><th id="hd_b_Corticosteroids.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Corticosteroids.Tf_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisolone, methylprednisolone</td></tr><tr><th id="hd_b_Corticosteroids.Tf_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Corticosteroids.Tf_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=6.1)</td></tr><tr><th id="hd_b_Corticosteroids.Tf_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Corticosteroids.Tf_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (fatal)</td></tr><tr><th id="hd_b_Corticosteroids.Tf_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Corticosteroids.Tf_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 months of oral prednisone</td></tr><tr><th id="hd_b_Corticosteroids.Tf_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Corticosteroids.Tf_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_Corticosteroids.Tf_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Corticosteroids.Tf_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-Aminosalicylic acid, isosorbide dinitrate, theophylline, insulin</td></tr></tbody></table></div></div></div><div id="Corticosteroids.Laboratory_Values_1"><h4>Laboratory Values</h4><div id="Corticosteroids.Tg" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Tg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Tg_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Corticosteroids.Tg_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Corticosteroids.Tg_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Corticosteroids.Tg_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Corticosteroids.Tg_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Corticosteroids.Tg_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;30</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.0</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HBV DNA &#x0003c;100 copies/mL</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 months</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.0</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methylprednisolone bolus</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 months</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">180</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.0</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisone: 5 mg daily</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 months</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">517</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.0</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alk P 356</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 days</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">600</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admission; HBeAg positive</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 days</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">700</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 days</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">830</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 months</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 days</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1140</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">980</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">34</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">220</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">36</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">50</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">41</td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Died</td></tr><tr><td headers="hd_h_Corticosteroids.Tg_1_1_1_1 hd_h_Corticosteroids.Tg_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;4.5</b></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Corticosteroids.Tg_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="Corticosteroids.TF.g.1"><p class="no_margin">Results and time sequence estimated from Figure 1.</p></div></dd></dl></div></div></div></div><div id="Corticosteroids.Comment_1"><h4>Comment</h4><p>Reactivation of hepatitis B in an HBsAg carrier can be followed by a severe episode of hepatitis as immunosuppression is withdrawn. The clinical syndrome is similar to acute hepatitis B and IgM anti-HBc may become detectable. The diagnosis can be made based upon reappearance and/or marked rise in HBV DNA levels. Many cases present as "acute-on-chronic" liver failure rather than classical acute liver failure. The prognosis is poor and antiviral therapy appears to have little effect once hepatic failure is present. HBsAg carriers who undergo immunosuppressive therapy with prednisone should be monitored and prophylaxis during the immunosuppression with an oral nucleoside analogue such as tenofovir or entecavir is appropriate.</p></div></div><div id="Corticosteroids.Case_3_Severe_acute_hepa"><h3>Case 3. Severe acute hepatitis following bolus, high dose methylprednisone therapy.(<a class="bk_pop" href="#Corticosteroids.REF.3">3</a>)</h3><p>A 43 year old woman with Graves disease developed worsening ophthalmopathy despite adequate control of thyroid function. She received orbital radiotherapy and was started on cycles of intravenous methylprednisolone (15/mg/kg) given over two days every two weeks. After the sixth infusion (6 weeks after starting), she was found to have elevations in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (264 U/L) and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> (120 U/L) and the infusions were held. Over the next six weeks, serum aminotransferase levels rose further (Table), with no or minor elevations in serum alkaline phosphatase, gamma glutamyltranspeptidase and bilirubin. However, the prothrombin index worsened (61%) and platelet count fell to 89,000/&#x000b5;L. Tests of hepatitis A, B and C were negative. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.immunoglobulin/">Immunoglobulin</a> levels were normal and tests for autoantibodies, including antinuclear antibody, smooth muscle antibody and liver-kidney microsomal antibody, were negative. A liver biopsy showed changes suggestive of chronic aggressive hepatitis with marked lymphocytic inflammation, interface hepatitis, and both focal and bridging necrosis. Because the histological and clinical features supported the diagnosis of severe autoimmune hepatitis, prednisone was initiated, with prompt improvements in serum aminotransferase levels. Prednisone doses were gradually reduced and ultimately withdrawn. Serum enzymes were normal within 2 months of starting prednisone and the dosage was gradually reduced and then withdrawn 3 months after initiation.</p><div id="Corticosteroids.Key_Points_2"><h4>Key Points</h4><div id="Corticosteroids.Th" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Th/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Th_lrgtbl__"><table><tbody><tr><th id="hd_b_Corticosteroids.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Corticosteroids.Th_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methylprednisolone</td></tr><tr><th id="hd_b_Corticosteroids.Th_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Corticosteroids.Th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular</td></tr><tr><th id="hd_b_Corticosteroids.Th_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Corticosteroids.Th_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ (serum enzyme elevations without jaundice)</td></tr><tr><th id="hd_b_Corticosteroids.Th_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Corticosteroids.Th_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td></tr><tr><th id="hd_b_Corticosteroids.Th_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Corticosteroids.Th_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 months</td></tr><tr><th id="hd_b_Corticosteroids.Th_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Corticosteroids.Th_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Corticosteroids.Laboratory_Values_2"><h4>Laboratory Values</h4><div id="Corticosteroids.Ti" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Ti/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Ti_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Corticosteroids.Ti_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Corticosteroids.Ti_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Corticosteroids.Ti_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Corticosteroids.Ti_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a><br />(U/L)</th><th id="hd_h_Corticosteroids.Ti_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1 hd_h_Corticosteroids.Ti_1_1_1_2 hd_h_Corticosteroids.Ti_1_1_1_3 hd_h_Corticosteroids.Ti_1_1_1_4 hd_h_Corticosteroids.Ti_1_1_1_5" colspan="5" scope="col" rowspan="1" style="text-align:center;vertical-align:top;">3 cycles of two days of pulse methylprednisolone given 2 weeks apart</td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">264</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">610</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>&#x000a0;and Alk P normal</td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1050</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">100</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ANA negative, Protime 61%</td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1419</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">183</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">im prednisolone started</td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">600</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral prednisone</td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">260</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">100</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 months</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">65</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">50</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 months</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 weeks</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Corticosteroids.Ti_1_1_1_1 hd_h_Corticosteroids.Ti_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;45</b></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;50</b></td><td headers="hd_h_Corticosteroids.Ti_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="Corticosteroids.TF.i.1"><p class="no_margin">Values and time sequence estimated from Figure 1.</p></div></dd></dl></div></div></div></div><div id="Corticosteroids.Comment_2"><h4>Comment</h4><p>An example of an acute hepatitis-like syndrome arising after pulse methylprednisolone therapy. These episodes arise typically 2 to 4 weeks after an early cycle of pulse therapy, and range in severity from an asymptomatic and transient rise in serum aminotransferase levels to an acute hepatitis and even fulminant hepatic failure. In this instance, the marked and persistent rise in serum enzymes coupled with liver histology suggesting chronic hepatitis led to a diagnosis of new-onset autoimmune hepatitis, despite the absence of serum autoantibodies or hypergammaglobulinemia. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoimmune-hepatitis/">Autoimmune hepatitis</a> may initially present in this fashion, without the typical pattern of serum autoantibodies during the early, anicteric phase. The diagnosis was further supported by the prompt improvements in serum enzymes with prednisone therapy. The acute hepatitis-like syndrome that can occur after pulses of methylprednisolone is best explained as a triggering of an underlying chronic autoimmune hepatitis caused by the sudden and profound immunosuppression followed by rapid withdrawal. This syndrome can be severe, and fatal instances have been reported. Whether reinitiation of corticosteroid therapy with gradual tapering and withdrawal is effective in ameliorating the course of illness is unclear, but anecdotal reports such as this one suggest that they are beneficial and should be initiated promptly on appearance of this syndrome. Long term follow up of such cases is also necessary to document that the autoimmune hepatitis does not relapse once corticosteroids are withdrawn again.</p></div></div></div><div id="Corticosteroids.PRODUCT_INFORMATION"><h2 id="_Corticosteroids_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Betamethasone &#x02013; Generic, Celestone&#x000ae;</p><p>Cortisone &#x02013; Generic</p><p>Dexamethasone &#x02013; Generic, Decadron&#x000ae;</p><p>Hydrocortisone &#x02013; Generic, Cortef&#x000ae;</p><p>Methylprednisolone &#x02013; Generic, Medrol&#x000ae;</p><p>Prednisolone &#x02013; Generic</p><p>Prednisone &#x02013; Generic</p><p>Triamcinolone &#x02013; Generic, Aristocort&#x000ae;, Kenacort&#x000ae;, Kenalog&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Glucocorticoids, Synthetic</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Betamethasone" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a> (Betamethasone)</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Corticosteroids.CHEMICAL_FORMULAS_AND_ST"><h2 id="_Corticosteroids_CHEMICAL_FORMULAS_AND_ST_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="Corticosteroids.Tj" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548400/table/Corticosteroids.Tj/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Corticosteroids.Tj_lrgtbl__"><table><thead><tr><th id="hd_h_Corticosteroids.Tj_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">DRUG</th><th id="hd_h_Corticosteroids.Tj_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Corticosteroids.Tj_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Corticosteroids.Tj_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Betamethasone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975144" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">378-44-9</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C22-H29-F-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975144" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134975144" alt="image 134975144 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cortisone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971011" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">53-06-5</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H28-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971011" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971011" alt="image 134971011 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dexamethasone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970849" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">50-02-2</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C22-H29-F-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970849" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134970849" alt="image 134970849 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hydrocortisone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971010" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">50-23-7</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H30-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971010" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971010" alt="image 134971010 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methylprednisolone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971422" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">83-43-2</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C22-H30-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971422" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971422" alt="image 134971422 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisolone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971175" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">50-24-8</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H28-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971175" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971175" alt="image 134971175 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970859" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">53-03-2</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H26-O5</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970859" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134970859" alt="image 134970859 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Corticosteroids.Tj_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Triamcinolone</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975389" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">124-94-7</a></td><td headers="hd_h_Corticosteroids.Tj_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H27-F-O6</td><td headers="hd_h_Corticosteroids.Tj_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975389" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134975389" alt="image 134975389 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Corticosteroids.CITED_REFERENCES"><h2 id="_Corticosteroids_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Corticosteroids.REF.1">Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyaline after long-term glucocorticoid therapy. <span><span class="ref-journal">Acta Hepato-Gastroenterologica. </span>1977;<span class="ref-vol">24</span>:415–8.</span> [<a href="/pubmed/74931" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 74931</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="Corticosteroids.REF.2">Hammond A, Ramersdorfer C, Palitzsch KD, Sch&#x000f6;lmerich J, Lock G. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>1999;<span class="ref-vol">124</span>:687–90.</span> [Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier] German. [<a href="/pubmed/10394348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10394348</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="Corticosteroids.REF.3">Marin&#x000f2; M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, Pollina LE, et al.  Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. <span><span class="ref-journal">J Endocrinol Invest. </span>2005;<span class="ref-vol">28</span>:280–4.</span> [<a href="/pubmed/15952415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15952415</span></a>]</div></dd></dl></div><div id="Corticosteroids.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Corticosteroids_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 30 October 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Corticosteroids.REF.zimmerman.1999">Zimmerman HJ. Corticosteroids. Drugs to treat rheumatic/musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 541.<div><i>(Expert review of hepatotoxicity of corticosteroids, focusing upon fatty liver and alcoholic hyaline-like changes with high doses or long term low doses).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.chitturi.2013">Chitturi S, Farrell GC. Corticosteroids. Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 613-4.<div><i>(Review of liver injury from corticosteroids mentions hepatic steatosis and acute liver injury following high dose methylprednisolone).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.schimmer.2011">Schimmer BP, Funder JW. Adrenocortical steroids. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1215-33.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.steinberg.1952.304">Steinberg H, Webb WM, Rafsky HA. Hepatomegaly with fatty infiltration secondary to cortisone therapy: case report. <span><span class="ref-journal">Gastroenterology. </span>1952;<span class="ref-vol">21</span>:304–9.</span> [<a href="/pubmed/14937220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14937220</span></a>]<div><i>(14 year old boy treated for rheumatic fever with cortisone developed marked hepatomegaly beginning on day 6, and by day 43 liver biopsy showed fat and inflammation, which resolved rapidly upon stopping therapy; liver biopsy 20 days later showed normal liver without steatosis).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hill.1963.766">Hill RB Jr, Droke WA. Production of fatty liver in the rat by cortisone. <span><span class="ref-journal">Proc Soc Exp Biol Med. </span>1963;<span class="ref-vol">114</span>:766–9.</span> [<a href="/pubmed/14120343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14120343</span></a>]<div><i>(Rats treated with cortisone developed fatty liver and increases in hepatic triglyceride levels).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.itoh.1977.415">Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyaline after long-term glucocorticoid therapy. <span><span class="ref-journal">Acta Hepato-Gastroenterologica. </span>1977;<span class="ref-vol">24</span>:415–8.</span> [<a href="/pubmed/74931" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 74931</span></a>]<div><i>(56 year old woman with systemic lupus treated with betamethasone for 16 months gained 24 pounds and developed insulin resistance, moderate increases in ALT [from 18 to 272 U/L] and Alk P [95 to 121 U/L] levels without jaundice; biopsy showed steatohepatitis and Mallory bodies: Case 1).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.iancu.1986.41">Iancu TC, Shiloh H, Dembo L. Hepatomegaly following short-term high-dose steroid therapy. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>1986;<span class="ref-vol">5</span>:41–6.</span> [<a href="/pubmed/3944744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3944744</span></a>]<div><i>(Among 140 children treated with prednisone [2-4 mg/kg/day], 19 developed hepatomegaly within 3-6 days, regressing with stopping treatment; liver biopsies showed glycogenosis and some degree of steatosis; no mention of ALT levels).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hoofnagle.1986.12">Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, et al.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. <span><span class="ref-journal">Ann Intern Med. </span>1986;<span class="ref-vol">104</span>:12–7.</span> [<a href="/pubmed/3940480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3940480</span></a>]<div><i>(Clinical trial of 4 week course of prednisolone [60 mg/day for 2 weeks, 30 mg/day for 2 weeks] in 15 patients with chronic hepatitis B found flares of hepatitis occurring in most patients 1-2 months after withdrawal that could be prolonged and lead to worsening of liver histology).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.wald.1991.277">Wald JA, Farr RS. Abnormal liver-function tests associated with long-term systemic corticosteroid use in subjects with asthma. <span><span class="ref-journal">J Allergy Clin Immunol. </span>1991;<span class="ref-vol">88</span>:277–8.</span> [<a href="/pubmed/1880328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1880328</span></a>]<div><i>(Retrospective analysis of 80 patients with asthma found mean ALT and Alk P levels were higher among 25 patients on &#x0201c;high dose&#x0201d; corticosteroids compared to those on no or low doses; 80% on high doses had at least one liver test abnormality compared to 23% on low doses and 5% on no corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.koga.1992.208">Koga Y, Kumashiro R, Yasumoto K, Shakado S, Ono N, Noguchi H, Nagata K, et al.  Two fatal cases of hepatitis B virus carriers after corticosteroid therapy for bronchial asthma. <span><span class="ref-journal">Intern Med. </span>1992;<span class="ref-vol">31</span>:208–13.</span> [<a href="/pubmed/1600269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1600269</span></a>]<div><i>(53 year old woman with asthma and HBsAg developed acute hepatitis 2-3 weeks after 1 month course of intravenous hydrocortisone [200-300 mg/day], with jaundice, hepatic failure and death 6 weeks later; 68 year old man with asthma and HBsAg developed symptoms and jaundice 1 month after 8 day course of intravenous hydrocortisone, with progression to acute liver failure and death).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.fong.1994.196">Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. <span><span class="ref-journal">Gastroenterology. </span>1994;<span class="ref-vol">107</span>:196–9.</span> [<a href="/pubmed/8020662" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8020662</span></a>]<div><i>(Among 10 patients with chronic hepatitis C treated with 7 week course of prednisone, most had rise in HCV RNA levels during therapy with fall in ALT and rebound afterwards, but without clinically apparent flares).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.gerolami.1997.236">Gerolami R, Mambrini P, Barthet M, Jean-Pastor MJ, Salducci J, Grimaud JC. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>1997;<span class="ref-vol">21</span>:236–7.</span> [Acute hepatitis caused by Solupred in a patient with Crohn disease] French. [<a href="/pubmed/9161506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9161506</span></a>]<div><i>(27 year old woman with Crohn disease received methylprednisolone [50 mg/day] followed by intravenous prednisone [60 mg/day] and developed abnormal liver tests 6 days later, ALT levels rising from normal to 11 times ULN, Alk P to 3.2 times ULN, ANA negative, resolving within 1 week of starting oral corticosteroids; elevations possibly due to acute glycogenosis).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hammond.1999.687">Hammond A, Ramersdorfer C, Palitzsch KD, Sch&#x000f6;lmerich J, Lock G. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>1999;<span class="ref-vol">124</span>:687–90.</span> [Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier] German. [<a href="/pubmed/10394348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10394348</span></a>]<div><i>(69 year old man with HBsAg carrier state and ulcerative colitis developed jaundice and progressive hepatic failure starting at the end of a 9 month course of prednisone [60 mg down to 5 mg/day], with appearance of HBV DNA, ALT 1140 U/L, and death 30 days later: Case 2).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.nanki.1999.3379">Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. <span><span class="ref-journal">Am J Gastroenterol. </span>1999;<span class="ref-vol">94</span>:3379.</span> [<a href="/pubmed/10566758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10566758</span></a>]<div><i>(53 year old woman with systemic lupus had rise of ALT [144 rising to 658 U/L] starting after 38 days of oral prednisolone therapy [20 mg/day], liver biopsy showing steatohepatitis; patient reported to have died of liver failure subsequently, but no clinical details given).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.shiota.2000.415">Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, Tsutsumi A, et al.  Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with "latent" chronic hepatitis B. <span><span class="ref-journal">Liver. </span>2000;<span class="ref-vol">20</span>:415–20.</span> [<a href="/pubmed/11092261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11092261</span></a>]<div><i>(46 year old woman with polyneuropathy developed hepatitis after each of 3 pulses of methylprednisolone [1 g/day for 3 days], twice with jaundice [bilirubin normal, rising to 20 mg/dL, ALT 500-1500 U/L, no detectable HBsAg, but &#x0201c;occult&#x0201d; HBV DNA identified in liver).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.weissel.2000.521">Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. <span><span class="ref-journal">Thyroid. </span>2000;<span class="ref-vol">10</span>:521.</span> [<a href="/pubmed/10907999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10907999</span></a>]<div><i>(71 year old woman with Graves disease developed hepatitis after fifth monthly cycle of high dose methylprednisolone [1 g/day for 3 days], with acute liver failure, death and massive necrosis on autopsy; patient also on methimazole and few clinical details given).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.marcocci.2001.3562">Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, et al.  Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001;<span class="ref-vol">86</span>:3562–7.</span> [<a href="/pubmed/11502779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11502779</span></a>]<div><i>(Controlled trial of intravenous methylprednisolone [15 mg/kg in 4 cycles] vs oral prednisone [starting at 100 mg/day] in 82 patients with Graves&#x02019; ophthalmopathy; one methylprednisolone treated patient had marked, asymptomatic increase in ALT at end of treatment, with recovery in 2 months; authors also mention an unpublished fatal case that they had seen before).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.dourakis.2002.1074">Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. <span><span class="ref-journal">Am J Gastroenterol. </span>2002;<span class="ref-vol">97</span>:1074–5.</span> [<a href="/pubmed/12003403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12003403</span></a>]<div><i>(67 year old woman with dermatomyositis developed jaundice after 8 days of intravenous prednisolone [75 mg/day] [bilirubin 10.8 mg/dL, ALT 545 U/L, Alk P 467 U/L, negative ANA], resolving on decreasing dose, but patient died of pneumonia shortly thereafter, liver histology showing severe fat without fibrosis).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.stravitz.2003.435">Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. <span><span class="ref-journal">Clin Liver Dis. </span>2003;<span class="ref-vol">7</span>:435–51.</span> [<a href="/pubmed/12879993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12879993</span></a>]<div><i>(Review of drugs that can cause steatohepatitis including glucocorticoids; mechanism unknown).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.candelli.2003.391">Candelli M, Nista EC, Pignataro G, Zannoni G, de Pascalis B, Gasbarrini G, Gasbarrini A. Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. <span><span class="ref-journal">J Intern Med. </span>2003;<span class="ref-vol">253</span>:391–2.</span> [<a href="/pubmed/12603510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12603510</span></a>]<div><i>(25 year old man with ulcerative colitis developed elevated ALT [106 U/L], fatty liver by ultrasound, and steatohepatitis on liver biopsy 40 days after starting oral methylprednisolone, ALT elevations and ultrasound changes resolving within 6 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.marin_.2004.403">Marin&#x000f3; M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. <span><span class="ref-journal">Thyroid. </span>2004;<span class="ref-vol">14</span>:403–6.</span> [<a href="/pubmed/15186621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15186621</span></a>]<div><i>(Among 800 patients with Graves ophthalmopathy treated with intravenous methylprednisolone, 7 [~1%] developed acute hepatitis-like illness following 3-6 courses, ages 30-63 years, arising 3-17 weeks after starting, 3 were jaundiced and died, 4 were asymptomatic [ALT 179-2490 U/L, Alk P 100-498 U/L], autoantibodies uncommon, resolving spontaneously in 9-22 weeks).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.salvi.2004.631">Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S, Beck-Peccoz P. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. <span><span class="ref-journal">Thyroid. </span>2004;<span class="ref-vol">14</span>:631–4.</span> [<a href="/pubmed/15320978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15320978</span></a>]<div><i>(43 year old woman with ophthalmopathy developed hepatitis after fourth course of methylprednisolone [ALT rising to 1152 U/L, ANA positive], responding to oral prednisone in tapering doses, but still on low doses of prednisone [2.5 mg/day] 6 years later).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.marin_.2005.280">Marin&#x000f2; M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, Pollina LE, et al.  Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. <span><span class="ref-journal">J Endocrinol Invest. </span>2005;<span class="ref-vol">28</span>:280–4.</span> [<a href="/pubmed/15952415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15952415</span></a>]<div><i>(43 year old woman with ophthalmopathy who developed marked ALT elevations [1419 U/L] with normal bilirubin and Alk P levels after 3 pulse cycles of methylprednisolone, ANA negative, but biopsy showed chronic aggressive hepatitis which responded to oral prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hofstee.2005.209">Hofstee HM, Nanayakkara PW, Stehouwer CD. Acute hepatitis related to prednisolone. <span><span class="ref-journal">Eur J Intern Med. </span>2005;<span class="ref-vol">16</span>:209–10.</span> [<a href="/pubmed/15967341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15967341</span></a>]<div><i>(46 year old woman with multiple sclerosis developed marked ALT elevations [peak levels 1095, ~1550 and ~2300 U/L with Alk P 140 U/L, LDH 473 U/L, ANA negative] 4-6 weeks after methylprednisolone pulse therapy on multiple occasions, always without jaundice and resolving rapidly each time).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.das.2006.314">Das D, Graham I, Rose J. Recurrent acute hepatitis in patient receiving pulsed methylprednisolone for multiple sclerosis. <span><span class="ref-journal">Indian J Gastroenterol. </span>2006;<span class="ref-vol">25</span>:314–6.</span> [<a href="/pubmed/17264438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17264438</span></a>]<div><i>(48 year old woman developed nausea and jaundice 6 weeks after a third course of high dose pulse methylprednisolone for multiple sclerosis [bilirubin ~12 rising to ~35 mg/dL, ALT 1625 U/L, Alk P 210 U/L, ANA negative], resolving in 1-2 months and recurring 1 year later after a fourth course).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.topal.2006.1868">Topal F, Ozaslan E, Akbulut S, K&#x000fc;&#x000e7;&#x000fc;kazman M, Y&#x000fc;ksel O, Altiparmak E. Methylprednisolone-induced toxic hepatitis. <span><span class="ref-journal">Ann Pharmacother. </span>2006;<span class="ref-vol">40</span>:1868–71.</span> [<a href="/pubmed/16926305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16926305</span></a>]<div><i>(47 year old woman developed jaundice one week after finishing 7 day course of methylprednisolone [32 mg/day] [bilirubin rising to 15 mg/dL, ALT 2478 U/L, Alk P 138 U/L, ANA negative], resolution in 8 weeks, also on topiramate which was also stopped, but restarted briefly).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.reu_.2007.356">Reu&#x000df; R, Retzlaff K, Vogel S, Franke FE, Oschmann P. Autoimmune hepatitis after high-dose intravenous methylprednisolone pulse in RR-MS. <span><span class="ref-journal">CEJ Med. </span>2007;<span class="ref-vol">2</span>:356–9.</span><div><i>(42 year old woman with multiple sclerosis developed elevations in ALT [1082 U/L] without jaundice 3 weeks after second pulse of intravenous methylprednisolone; liver biopsy showed necrosis, collapse and fibrosis, levels slowly improved; no mention of ANA or bilirubin levels).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.le_moli.2007.357">Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. <span><span class="ref-journal">Thyroid. </span>2007;<span class="ref-vol">17</span>:357–62.</span> [<a href="/pubmed/17465867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17465867</span></a>]<div><i>(Among 27 patients with Graves ophthalmopathy receiving 1-4 pulses of methylprednisolone, 7 had transient ALT elevations [peak level 120 U/L] shortly after infusion, all resolved and none were jaundiced).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.takahashi.2008.5474">Takahashi A, Kanno Y, Takahashi Y, Sakamoto N, Monoe K, Saito H, Abe K, et al.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report. <span><span class="ref-journal">World J Gastroenterol. </span>2008;<span class="ref-vol">14</span>:5474–7.</span> [<a href="/pmc/articles/PMC2744174/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2744174</span></a>] [<a href="/pubmed/18803363" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18803363</span></a>]<div><i>(43 year old woman with multiple sclerosis developed acute hepatitis 1 month after third course of pulse methylprednisolone [1 g/day for 3 days] [bilirubin 3.4 mg/dL, ALT 1067 U/L, Alk P 377 U/L, IgG 1370 mg/dL, ANA negative] with bilirubin rising to 19.1 mg/dL, attributed to beta interferon; but developed hepatitis again 2 weeks after a subsequent pulse of methylprednisolone [bilirubin 1.7 mg/dL, ALT 875 U/L, Alk P 214 U/L, IgG 1785 mg/dL and ANA 1:80], resolving with oral prednisolone therapy).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.rivero_fern_ndez.2008.720">Rivero Fern&#x000e1;ndez M, Riesco JM, Moreira VF, Moreno A, L&#x000f3;pez San Rom&#x000e1;n A, Arranz G, Ruiz Del Arbol L. <span><span class="ref-journal">Rev Esp Enferm Dig. </span>2008;<span class="ref-vol">100</span>:720–3.</span> [Recurrent acute liver toxicity from intravenous methylprednisolone] Spanish. [<a href="/pubmed/19159178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19159178</span></a>]<div><i>(57 year old woman with multiple sclerosis developed ALT elevations after each of 3 pulse cycles of methylprednisolone [peak ALT 1223, 833 and 2685 U/L, Alk P 113 and 115 U/L, ANA negative] without jaundice and with rapid resolution, biopsy showing acute hepatitis with &#x0201c;lytic&#x0201d; necrosis).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were attributed to corticosteroid therapy or methylprednisolone).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hoofnagle.2009.s156">Hoofnagle JH. Reactivation of hepatitis B. <span><span class="ref-journal">Hepatology. </span>2009;<span class="ref-vol">49</span>(5) Suppl:S156–65.</span> [<a href="/pubmed/19399803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19399803</span></a>]<div><i>(Review of reactivation of hepatitis B as caused by chemotherapy or immunosuppression).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.loraschi.2010.52">Loraschi A, Banfi P, Mauri M, Sessa F, Bono G, Cosentino M. Hepatotoxicity after high-dose methylprednisolone for demyelinating disease. <span><span class="ref-journal">Clin Neuropharmacol. </span>2010;<span class="ref-vol">33</span>:52–4.</span> [<a href="/pubmed/19935411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19935411</span></a>]<div><i>(One man and one woman, ages 33 and 27 years with demyelinating disease developed abnormal ALT levels [1042 U/L and 122 U/L] 5 and 1 week after starting high dose methylprednisolone therapy [4 and 6 days of 2.5 and 4.5 g], resolving rapidly; no mention of symptoms or jaundice).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to methylprednisolone or other corticosteroids).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.gutkowski.2011.656">Gutkowski K, Chwist A, Hartleb M. Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature. <span><span class="ref-journal">Hepat Mon. </span>2011;<span class="ref-vol">11</span>:656–61.</span> [<a href="/pmc/articles/PMC3227489/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3227489</span></a>] [<a href="/pubmed/22140391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22140391</span></a>]<div><i>(24 year old woman with multiple sclerosis developed jaundice 4 weeks after a pulse of methylprednisolone and 1 week after 2 doses of interferon beta [bilirubin 17.9 mg/dL, ALT 740 U/L, Alk P 186 U/L, prothrombin index 35%, SMA &#x0003e;1:320], resolving spontaneously, but recurring after another pulse of methylprednisolone with interferon beta [bilirubin 7.3 mg/dL, ALT 1129 U/L, Alk P 164 U/L], again resolving spontaneously).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.furutama.2011.291">Furutama D, Kimura F, Shinoda K, Maeda T, Tanaka T, Ohsawa N. Recurrent high-dose intravenous methylprednisolone succinate pulse therapy-induced hepatopathy in a patient with multiple sclerosis. <span><span class="ref-journal">Med Princ Pract. </span>2011;<span class="ref-vol">20</span>:291–3.</span> [<a href="/pubmed/21455003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21455003</span></a>]<div><i>(11 year old girl with multiple sclerosis had 3 episodes of marked serum ALT elevations [peak levels ~700-1400 U/L] 1-2 months after bolus therapy with methylprednisolone, with minimal symptoms and no jaundice or bilirubin elevations).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, of which none were attributed to corticosteroids or methylprednisolone).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.carrier.2013.100">Carrier P, Godet B, Crepin S, Magy L, Debette-Gratien M, Pillegand B, Jacques J, et al.  Acute liver toxicity due to methylprednisolone: consider this diagnosis in the context of autoimmunity. <span><span class="ref-journal">Clin Res Hepatol Gastroenterol. </span>2013;<span class="ref-vol">37</span>:100–4.</span> [<a href="/pubmed/23318289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23318289</span></a>]<div><i>(30 year old woman with multiple sclerosis developed jaundice 3 weeks after a second bolus dose of methylprednisone [bilirubin 25.8 mg/dL, ALT 547 U/L, Alk P 141 U/L, ANA negative], with rapid resolution on stopping and recurrence 2 and 5 years later with subsequent single bolus doses of methylprednisone [peak bilirubin 6.6 and 9.6 mg/dL, ALT 415 and 2826 U/L and Alk P 60 and 148 U/L, latency 10-20 days]).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.dagnolo.2013.199">D'Agnolo HM, Drenth JP. High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature. <span><span class="ref-journal">Neth J Med. </span>2013;<span class="ref-vol">71</span>:199–202.</span> [<a href="/pubmed/23723114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23723114</span></a>]<div><i>(48 year old woman developed abdominal pain and nausea 19 days after high dose methylprednisolone for multiple sclerosis [bilirubin 1.7 mg/dL, ALT 3028 U/L, GGT 182 U/L], resolving within the following few weeks; by history, she had a similar event 14 years earlier, but did not develop clinically apparent liver injury after 3 subsequent courses of oral dexamethasone [200 mg/day]).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.melamud.2014.180">Melamud B, Lurie Y, Goldin E, Levi I, Esayag Y. Methylprednisolone-induced liver injury: a diagnostic challenge. <span><span class="ref-journal">Isr Med Assoc J. </span>2014;<span class="ref-vol">16</span>:180–1.</span> [<a href="/pubmed/24761710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24761710</span></a>]<div><i>(52 year old man with Graves disease developed liver injury within a few weeks of intravenous methylprednisolone, which recurred when he received a second course [bilirubin 3.4 mg/dL, ALT 465 U/L, Alk P 80 U/L], resolving on no therapy within 7 months).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to budesonide or methyl prednisone or other corticosteroids).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 2 were attributed to high dose methylprednisolone, but none to budesonide or other corticosteroids).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.juan.2014.395">Juan J, Feld JJ. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. <span><span class="ref-journal">Curr Opin Rheumatol. </span>2014;<span class="ref-vol">26</span>:395–403.</span> [<a href="/pubmed/24841230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24841230</span></a>]<div><i>(Review of reactivation of hepatitis B and C by chemotherapeutic and immune-modifying agents including corticosteroid based therapies).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.ferraro.2015.153">Ferraro D, Mirante VG, Losi L, Villa E, Simone AM, Vitetta F, Federzoni L, et al.  Methylprednisolone-induced toxic hepatitis after intravenous pulsed therapy for multiple sclerosis relapses. <span><span class="ref-journal">Neurologist. </span>2015;<span class="ref-vol">19</span>:153–4.</span> [<a href="/pubmed/26075468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26075468</span></a>]<div><i>(Short summaries of 4 cases of liver injury after high dose intravenous methyl prednisolone therapy of multiple sclerosis, all 4 were women, ages 24 to 50 years, usually with onset within 1 month, peak ALT levels of 260-494 U/L, evidently without jaundice, and resolving spontaneously, but recurring with reexposure).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF48">High-dose intravenous methylprednisolone: liver injury. <span><span class="ref-journal">Prescrire Int. </span>2015;<span class="ref-vol">24</span>:270.</span> [<a href="/pubmed/26688906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26688906</span></a>]<div><i>(Summary of a recent Canadian drug regulatory agency review of 32 cases [4 new] of acute liver injury after intravenous methylprednisolone therapy which were accompanied by jaundice in 10, recurred with rechallenge in 11 and resulted in death in 4).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.davidov.2016.55">Davidov Y, Har-Noy O, Pappo O, Achiron A, Dolev M, Ben-Ari Z. Methylprednisolone-induced liver injury: Case report and literature review. <span><span class="ref-journal">J Dig Dis. </span>2016;<span class="ref-vol">17</span>:55–62.</span> [<a href="/pubmed/26676833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26676833</span></a>]<div><i>(23 year old Israel woman with multiple sclerosis developed jaundice three weeks after receiving a 3 day course of high dose methylprednisolone [bilirubin 6.9 mg/dL, ALT 2011 U/L, Alk P 148 U/L, INR 1.18], biopsy showing zone 3 necrosis and inflammation, resolving rapidly; had a previous history of similar episode 3 years earlier).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.moleti.2016.259">Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campenn&#x000ec; A, Morelli S, Puxeddu E, et al.  Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy. <span><span class="ref-journal">Endocrine. </span>2016;<span class="ref-vol">54</span>:259–68.</span> [<a href="/pubmed/27003434" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27003434</span></a>]<div><i>(2 patients with Graves&#x02019; ophthalmopathy developed liver enzyme elevations during high dose methylprednisolone therapy, 58 year old man and 50 year old women, arising after 5th and 3rd weekly infusions [ALT 809 and 822 U/L, GGT 112 and normal, bilirubin normal or not given], with spontaneous resolution 12 and 16 weeks after stopping).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.sayin.2016.s45">Sayin R, Gokgul A, Ebinc S, Dulger AC, Tombul T. Clinical overlap of multiple sclerosis and autoimmune hepatitis: three cases. <span><span class="ref-journal">J Coll Physicians Surg Pak. </span>2016;<span class="ref-vol">26</span>(6) Suppl:S45–7.</span> [<a href="/pubmed/27376220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27376220</span></a>]<div><i>(Description of 3 patients with multiple sclerosis and features of autoimmune hepatitis, two of whom were receiving interferon beta and the third with preexisting autoimmune hepatitis found to have brain imaging changes suggestive of multiple sclerosis).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.dumortier.2017.497">Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, et al.  Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey. <span><span class="ref-journal">Clin Res Hepatol Gastroenterol. </span>2017;<span class="ref-vol">41</span>:497–501.</span> [<a href="/pubmed/28438569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28438569</span></a>]<div><i>(27 year old woman with multiple sclerosis treated with multiple agents had repeated bouts of acute liver injury arising within a month of pulse methylprednisolone therapy that was sometimes clinically apparent [bilirubin 3.7 mg/dL, ALT 1704 U/L, GGT 124 U/L] and resolved within a few months of stopping, later tolerating fingolimod; review of a French pharmacovigilance registry identified 4 other cases of severe injury attributed to high dose, pulses of methylprednisolone).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.abramavicius.2017.e8159">Abramavicius S, Velickiene D, Kadusevicius E. Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report. <span><span class="ref-journal">Medicine (Baltimore). </span>2017;<span class="ref-vol">96</span>:e8159. </span> [<a href="/pmc/articles/PMC5626305/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5626305</span></a>] [<a href="/pubmed/28953662" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28953662</span></a>]<div><i>(74 year old woman with Graves&#x02019; ophthalmopathy was treated with methimazole and pulses of methylprednisolone and developed mild-to-moderate ALT elevations after the 4th pulse that continued until the 9th pulse and eventually resolved despite continuing both drugs).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.bresteau.2018.bcr2017223670">Bresteau C, Prevot S, Perlemuter G, Voican C. Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse. <span><span class="ref-journal">BMJ Case Rep. </span>2018;<span class="ref-vol">2018</span>:bcr2017223670. </span> [<a href="/pmc/articles/PMC5847962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5847962</span></a>] [<a href="/pubmed/29507031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29507031</span></a>]<div><i>(35 year old woman with 13 year history of multiple sclerosis developed acute liver injury 2 months after a 5 day course of high dose methylprednisolone [bilirubin 2.9 mg/dL, ALT 1512 U/L, Alk P 86 U/L, GGT 109 U/L], resolving within 6 weeks).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.nociti.2018.e00968">Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, Marrone G, et al.  Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. <span><span class="ref-journal">Brain Behav. </span>2018;<span class="ref-vol">8</span>:e00968. </span> [<a href="/pmc/articles/PMC5991562/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5991562</span></a>] [<a href="/pubmed/29729087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29729087</span></a>]<div><i>(Among 175 patients with multiple sclerosis receiving 251 cycles of high dose intravenous methylprednisolone, 21 [8.6%] developed de novo ALT elevations after therapy, which were transient and mild in 15 but severe in 6 [3.4%: bilirubin 1.3 to 10.8 mg/dL, ALT 778 to 2956 U/L, Alk P 91 to 350 U/L, hepatocellular in all], resolving in 4 subjects but evolving into chronic hepatitis suspected to be autoimmune in 2 both of whom required long term immunosuppressive therapy).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.adamec.2018.43">Adamec I, Pavlovi&#x00107; I, Pavi&#x0010d;i&#x00107; T, Ru&#x00161;ka B, Habek M. Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis. <span><span class="ref-journal">Mult Scler Relat Disord. </span>2018;<span class="ref-vol">25</span>:43–5.</span> [<a href="/pubmed/30032042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30032042</span></a>]<div><i>(Three women, ages 37 to 46 years, with multiple sclerosis developed acute liver injury after infusions of high dose, intravenous methylprednisolone [ALT 2259, 395 and 1340 U/L], recurring with milder ALT elevations upon reexposure [ALT 140, 134, and 85 U/L], and with no evidence of injury with lower doses).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.rotondo.2018.e226687">Rotondo E, Graziosi A, Di Stefano V, Mohn AA. Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis. <span><span class="ref-journal">BMJ Case Rep. </span>2018;<span class="ref-vol">11</span>:e226687. </span> [<a href="/pmc/articles/PMC6301543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6301543</span></a>] [<a href="/pubmed/30567201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30567201</span></a>]<div><i>(16 year old girl with recent onset of multiple sclerosis developed an acute hepatitis a month after a 5 day course of intravenous methylprednisolone [bilirubin 2.1 mg/dL, ALT 2438 U/L, GGT 68 U/L], resolving spontaneously within 2 months of onset).</i></div></div></li><li><div class="bk_ref" id="Corticosteroids.REF.zoubek.2019.825">Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hern&#x000e1;ndez N, Crespo J, Contreras F, Medina-C&#x000e1;liz I, et al.  Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <span><span class="ref-journal">United European Gastroenterol J. </span>2019;<span class="ref-vol">7</span>:825–37.</span> [<a href="/pmc/articles/PMC6620870/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6620870</span></a>] [<a href="/pubmed/31316787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31316787</span></a>]<div><i>(Three women, ages 31 to 36 years, with multiple sclerosis developed acute liver injury 2-6 weeks after receiving a 3-7 day course of intravenous methylprednisolone [bilirubin 3.6, 0.8 and 13.9 mg/dL, ALT 2194, 630 and 2737 U/L, Alk P 229, 193 and 169 U/L], resolving spontaneously and recurring with reexposure in two patients).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548400</span><span class="label">PMID: <a href="/pubmed/31643719" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643719</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Copper/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Crizotinib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548400&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548400/?report=reader">PubReader</a></li><li><a href="/books/NBK548400/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548400" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548400" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Corticosteroids. [Updated 2020 Oct 30].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548400/pdf/Bookshelf_NBK548400.pdf">PDF version of this page</a> (232K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Corticosteroids/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Corticosteroids: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Corticosteroids" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Corticosteroids: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4861544" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4861544" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4861544" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14047047" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[PRINCIPLES OF CORTISONE THERAPY].</a><span class="source">[Urologe. 1963]</span><div class="brieflinkpop offscreen_noflow">[PRINCIPLES OF CORTISONE THERAPY].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">KAISER H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Urologe. 1963 Jul 15; 2:203-10. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14103588" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[FEVER IN CHILDREN. (3)].</a><span class="source">[Chiryo. 1963]</span><div class="brieflinkpop offscreen_noflow">[FEVER IN CHILDREN. (3)].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">SATOMI M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Chiryo. 1963; 45:2223-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14058448" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[PROBLEMS IN THE SIDE-EFFECTS OF ADRENAL CORTEX HORMONE THERAPY OF SKIN DISEASES].</a><span class="source">[Nisshin Igaku Jpn J Med Prog. ...]</span><div class="brieflinkpop offscreen_noflow">[PROBLEMS IN THE SIDE-EFFECTS OF ADRENAL CORTEX HORMONE THERAPY OF SKIN DISEASES].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">NOHARA N, TSUKINOKI K, TODA M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nisshin Igaku Jpn J Med Prog. 1963 Mar; 50:139-58. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29859017" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma.</a><span class="source">[Cochrane Database Syst Rev. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kirkland SW, Cross E, Campbell S, Villa-Roel C, Rowe BH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2018 Jun 2; 6:CD012629. Epub 2018 Jun 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9333538" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Natural and synthetic glucocorticoids in the racing horse: a review of the literature].</a><span class="source">[Dtsch Tierarztl Wochenschr. 1996]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Natural and synthetic glucocorticoids in the racing horse: a review of the literature].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Klaus AM, Hapke HJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dtsch Tierarztl Wochenschr. 1996 Dec; 103(12):494-500. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643719" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643719" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467d7bb1d385378af09e9f">Corticosteroids - LiverTox</a><div class="ralinkpop offscreen_noflow">Corticosteroids - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:39:39-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8CFAB10466D5810000000003A00108&amp;ncbi_session=CE8CFAB10467D7A1_0928SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548400%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548400&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548400/&amp;ncbi_pagename=Corticosteroids - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CFAB10467D7A1_0928SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>